METHOCLOPRAMIDE
| StockNo |
Product description |
| EB0280-410-14 |
METHOCLOPRAMIDE
SYRUP 125 ML |
-
- COMPOSITION:
Methoclopramide hydrochloride 5 mg in 5 ml syrup
ACTION:
Antiemetic preparation of synthetic origin, similar to the
neuroleptics with antidopaminergic activity by action type. It
exerts a central inhibiting action on hemoreceptors in the trigger
zones of medulla oblongata, but does not exercise any depressive
effect on central and peripheral nervous systems. Its antiemetic
effect is about 20 times stronger than that of chlorpromasine.
Metoclopramide has a regulating influence on the digestive system
functions, it stimulates gastric motility without increasing the
secretion of gastric juice.
PHARMACOKINETICS:
At oral administration Methoclopramide is quickly and fully
absorbed, the maximum plasma level being reached 30 to 120 min after
intake. It metabolizes in liver, 20 % of the preparation are
eliminated with urine in unchanged form. Its therapeutic effect on
the digestive tract lasts 20-40 min, and the antiemetic - 1-12 h.
INDICATIONS:
Vomiting of central and peripheral origin. The preparation is
applied as a pre-medication in gastric and duodenum operations.
Complex therapy of gastritis, dyskinesia of biliary tract,
meteorism, peptic ulcer of the stomach and duodenum, reflux
oesophagitis, radiation sickness, etc.
CONTRAINDICATIONS:
Extrapyramidal therapy, epilepsy, gastrointestinal hemorrhages,
mechanical obstruction of the intestines, pheochromocytosis,
hypersensitivity to the preparation and to procaine, procainamide. |
SIDE EFFECTS:
Extrapyramidal symptoms, sleep disturbances and libido disturbances
are possible after prolonged therapy with Methoclopramide.
PRECAUTIONS:
It should be taken into consideration that application of
Methoclopramide to patients, undergoing systemic therapy with
tranquilizers and antidepressants, may lead to increased
fatigability. By patients with heavy hepatic and kidney diseases the
doses should be decreased.
DRUG INTERACTIONS:
Methoclopramide potentiates the action of paracetamol but it
decreases the effects of anticholinergic drugs and chimecromon.
Extrapyramidal disturbances during combined therapy with
MAO-inhibitors, neuroleptics and tricyclic antidepressants are
enhanced.
DOSAGE AND ADMINISTRATION:
The preparation is applied to adults in doses from 5 to 20 mg, 3-4
times daily, before meals.
MEDICINAL FORM AND PACKAGE:
Syrup in vials of 125 ml.
STORAGE:
At moderate temperature (15-30 C), in a place protected from light.
EXPIRY:
2 (two) years. |
